Physician profile
Donna E Hendley
NPI 1093885873
$3,993.97
in general payments reported to CMS, 2019-2025
48 companies · $2,014 in 2025
The $2,014 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.42 · 2023: $561 · 2024: $1,321 · 2025: $2,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,896.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $343.62 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $299.63 | 2024-2025 | Imfinzi, Lynparza, Calquence |
| Abbvie INC. | $271.62 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $242.36 | 2023-2024 | Reblozyl |
| Daiichi Sankyo INC. | $212.75 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $204.55 | 2024-2025 | |
| Gilead Sciences, INC. | $198.69 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $174.79 | 2023-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $148.54 | 2024-2025 | |
| Genentech USA, INC. | $141.51 | 2024-2025 | Tecentriq, Alecensa, Itovebi |
| Celgene Corporation | $129.42 | 2024-2025 | Reblozyl, Pomalyst, Breyanzi |
| Janssen Biotech, INC. | $116.15 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Lilly USA, LLC | $115.09 | 2021-2024 | Verzenio, Jaypirca |
| Jazz Pharmaceuticals INC. | $85.53 | 2024-2025 | |
| Astellas Pharma US INC | $81.14 | 2023-2025 | Vyloy, Padcev |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75.63 | 2023-2025 | Ninlaro, Iclusig |
| Coherus Oncology, INC. | $74.45 | 2023-2025 | Udenyca, Loqtorzi |
| Incyte Corporation | $69.53 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $68.83 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.19 | 2024-2025 | |
| Pfizer INC. | $64.61 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $59.58 | 2023-2025 | Qinlock, Romvimza |
| Adc Therapeutics America, INC. | $55.92 | 2023-2025 | |
| Pharmaessentia USA Corporation | $52.81 | 2024-2025 | Besremi |
| Glaxosmithkline, LLC. | $48.98 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Beigene USA, INC. | $47.03 | 2023-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $43.03 | 2024-2025 | Xpovio |
| Mirati Therapeutics, INC. | $37.77 | 2024 | Krazati |
| Agios Pharmaceuticals, INC. | $35.62 | 2025 | Pyrukynd |
| Exelixis INC. | $34.17 | 2024 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $31.88 | 2024-2025 | Monoferric |
| Geron Corporation | $28.32 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $27.46 | 2025 | Erleada |
| Stemline Therapeutics INC. | $26.49 | 2025 | Orserdu |
| Sobi, INC | $24.94 | 2024 | |
| Cycle Pharmaceuticals INC | $24.64 | 2025 | Phyrago |
| Aveo Pharmaceuticals, INC. | $24.11 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.88 | 2025 | Onivyde |
| Legend Biotech USA INC. | $22.42 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $20.33 | 2025 | Ultomiris |
| Tempus Ai, INC | $19.99 | 2024 | |
| Acrotech Biopharma INC. | $19.45 | 2024 | Beleodaq |
| Sun Pharmaceutical Industries INC. | $18.91 | 2025 | |
| Iovance Biotherapeutics, INC. | $18.19 | 2025 | Amtagvi |
| Sumitomo Pharma America, INC. | $17.55 | 2025 | Orgovyx |
| Seagen INC. | $16.90 | 2023 | Adcetris |
| Taiho Oncology, INC. | $15.31 | 2024 | |
| Caris Mpi, INC. | $14.66 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Hendley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.